GL261-Luc Cells

GL261-Luc cells are a bioluminescent derivative of the murine GL261 glioma cell line engineered to stably express a luciferase reporter gene. Following administration of the luciferin substrate, these cells emit a quantifiable luminescent signal proportional to viable tumor cell number, enabling sensitive and non-invasive monitoring of tumor growth and therapeutic response. GL261-Luc cells retain many of the biological and immunogenic properties of the parental GL261 glioma model, including aggressive growth behavior and compatibility with syngeneic immunocompetent mouse models. Because the parental GL261 line originates from murine glioma, GL261-Luc cells are particularly valuable for studying glioblastoma biology in the context of an intact immune system.

GL261-Luc cells are extensively used in orthotopic intracranial and subcutaneous glioma models for longitudinal in vivo bioluminescence imaging. The stable luciferase expression enables real-time assessment of tumor establishment, progression, invasion, recurrence, and response to therapy without requiring invasive procedures at multiple time points. These cells are widely applied in preclinical neuro-oncology research evaluating chemotherapeutics, radiation therapy, immune checkpoint blockade, CAR-T cell therapies, cancer vaccines, oncolytic viruses, and nanoparticle-based drug delivery systems. In vitro, GL261-Luc cells are also suitable for viability assays, cytotoxicity testing, migration and invasion studies, and high-throughput therapeutic screening workflows using luminescence-based readouts.

As a syngeneic glioma model, GL261-Luc cells are particularly important for investigating tumor-immune interactions, neuroinflammation, and mechanisms of immune evasion within the glioblastoma microenvironment. However, luciferase vector systems, promoter configurations, and selection strategies may differ between independently generated variants, potentially affecting signal intensity and long-term reporter stability. Researchers should therefore validate luciferase activity, growth kinetics, and immunologic characteristics under their specific experimental conditions prior to use in quantitative imaging studies or therapeutic evaluation.